Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sherry Basile

Physician Assistant, Medical Greensburg, PA Physician Assistant

NPI 1265539977 CMS profile 10837248

530 South St, Suite 300, Greensburg, PA 15601

Open in the dashboard

General payments

$17,810

1,039 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sherry Basile of Greensburg, PA is reported in the CMS Open Payments database as having received $17,810 across 1,039 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,876 124
2024 General $3,649 184
2023 General $3,928 215
2022 General $3,716 268
2021 General $3,641 248

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sherry Basile
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Sherry Basile were reported at $2,876. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Sherry Basile Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,641 $156 $41–$563 $132
2022 $3,716 $185 $55–$649 $149
2023 $3,928 $199 $58–$717 $160
2024 $3,649 $206 $62–$740 $164
2025 $2,876 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,759 258 payments
  2. Lilly USA, LLC $1,950 103 payments
  3. CeQur Corporation $1,452 4 payments
  4. Mannkind Corporation $1,371 81 payments
  5. Dexcom, Inc. $1,142 98 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $1,137 64 payments
  7. Abbott Laboratories $839 89 payments
  8. Xeris Pharmaceuticals, Inc. $716 34 payments
  9. AstraZeneca Pharmaceuticals LP $587 18 payments
  10. Insulet Corporation $573 28 payments
  11. Other $5,284 262 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,535 1,033 payments
  2. Education $215 5 payments
  3. Gift $59 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $2,127 216 payments
  2. Ozempic $1,963 215 payments
  3. CeQur Simplicity $1,452 4 payments
  4. AFREZZA $1,295 80 payments
  5. Dexcom G6 Transmitter $994 83 payments
  6. MOUNJARO $936 43 payments
  7. TRULICITY $727 40 payments
  8. JARDIANCE Diabetes $697 39 payments
  9. JARDIANCE Diabetes $674 39 payments
  10. FARXIGA $587 18 payments
  11. Other $10,471 588 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 104 drugs

Part D claims

8,927

Median for Physician Assistant: 241

Drug cost

$3,633,709

Median for Physician Assistant: $4,110

Branded share of claims

66.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 1,078 $1,176,474
Jardiance Empagliflozin Brand 431 $388,812
Trulicity Dulaglutide Brand 186 $217,676
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 180 $201,351
Farxiga Dapagliflozin Propanediol Brand 220 $195,001
Mounjaro Tirzepatide Brand 172 $182,072
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 99 $85,691
Tradjenta Linagliptin Brand 131 $84,019
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 75 $80,529
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 43 $72,528

The 10 drugs with the highest cost, of 104 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$414 431 —
AFREZZA
$367 — —
MOUNJARO
$178 172 —
GVOKE HYPOPEN
$143 — —
Kerendia
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

1,039 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record